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CONDENSATION 
This article presents a comprehensive description of the causes, evaluation, and treatment of 
non-candidal vaginitis. 
Short title: Non-Candidal Vaginitis Review 
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ABSTRACT 
Vaginitis is one of the most common causes of patient visits to gynecologists, primary care 
providers, and urgent care centers. However, many women leave without a clear diagnosis or 
experience recurrent symptoms despite treatment. The three most common etiologies of 
vaginitis are trichomonas, bacterial vaginosis, and vulvovaginal candidiasis, which account for 
an estimated 70% of cases. The remaining 30% may be related to other causes of vaginitis, 
including atrophic vaginitis, desquamative inflammatory vaginitis, and vaginal erosive disease.  
The purpose of this review is to describe the non-candidal causes of acute and recurrent 
vaginitis, with the goal of improving the likelihood of accurate diagnosis as well as efficient and 
effective therapy.  We excluded candidal vaginitis from our review, as there was a recently 
published review on this topic in the American Journal of Obstetrics and Gynecology. 
The clinical presentation and evaluation of patients with symptoms of vaginitis can be triaged 
into one of two diagnostic pathways: non-inflammatory and inflammatory vaginitis. The most 
common non-inflammatory cause is bacterial vaginosis. Features such as irritation, purulent 
discharge, and the presence of polymorphonuclear neutrophils are more suggestive of an 
inflammatory process.  Trichomoniasis is the most common cause of inflammatory vaginitis. 
Other well-described forms of inflammatory vaginitis include atrophic vaginitis, desquamative 
inflammatory vaginitis, and erosive disease. We present a review of the pathogenesis, 
symptoms, exam findings, diagnostic testing, and treatment for each of these causes of non-
candidal vaginitis. 
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INTRODUCTION 
Symptoms of vaginitis (discharge, irritation, odor, itching, swelling, etc.) are among the 
most frequent causes of patient visits to gynecologists, primary care providers and urgent care 
centers
1-2
 and may account for up to 10 million office visits per year. It is estimated that 7%-
72% of women leave the clinician’s office without a clear diagnosis or return within a short 
interval due to a recurrence of symptoms.
1,4
 
5
Many practitioners utilize a limited spectrum of 
common potential differential diagnoses for women who suffer from symptoms of vaginitis, 
applying only the three most likely etiologies, (trichomonas, bacterial vaginosis (BV), and 
vulvovaginal candidiasis).
6
  While these three conditions cause of up to 70% of abnormal vaginal 
symptoms, they are not the only causes of vaginitis. 
1
 
5
The differential diagnosis should be 
expanded, especially in women with persistent symptoms.   
 In 1954, Franken first described a non-infectious, “purulent” form of vaginitis in a young 
girl that responded well to estrogen therapy. Since that time, several forms of non-infectious, 
exudative and inflammatory types of vaginitis have been described.  The purpose of this review 
is to provide a diagnostic algorithm based on examination findings consistent with 
inflammation.  We also offer an expanded description of the causes of incident and recurrent 
vaginitis with the goal of improving diagnostic accuracy and the initiation of appropriate 
therapy.  As a review of candidiasis was recently published by Sobel et al.,
9
 our review will focus 
on BV, trichomoniasis, and other causes of acute and recurrent vaginal symptoms.   
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A Diagnostic Aid: Inflammatory or Non-Inflammatory? 
The clinical presentation and evaluation of patients with vaginal symptoms can be 
categorized into one of two diagnostic pathways: non-inflammatory or inflammatory (See 
Figure 1). Inflammatory refers to the presence of polymorphonuclear neutrophils (PMNs) on 
microscopic examination of vaginal discharge or physical findings such as erythema and edema. 
Non-inflammatory conditions consist of an absence of the aforementioned symptoms and 
absence of PMNs on microscopy in a woman with vaginal complaints such as odor or abnormal 
discharge.  
The inflammatory forms of vaginitis share a common spectrum of clinical presentation 
but vary in etiology and treatment responsiveness. The most common forms of inflammatory 
vaginitis are trichomoniasis infection and candidiasis. Other well-described but less common 
forms of inflammatory vaginitis are hypoestrogenic or atrophic vaginitis, desquamative 
inflammatory vaginitis (DIV), and multi-mucosal erosive diseases (e.g. erosive lichen planus, 
pemphigus vulgaris, and cicatricial (mucous membrane) pemphigoid).
7
 
5,10
These are 
autoimmune disorders that result in erosions or blisters that affect mucosal surfaces such as 
the mouth, esophagus, eye-lid, vagina, and vulva.   BV is the most common non-inflammatory 
vaginal condition, but certain forms of vulvovaginal candidiasis or mixed infections can also be 
non-inflammatory.
8,6
 
Bacterial Vaginosis  
Forty to fifty percent of women with vaginal complaints will be diagnosed with BV 
making it the most prevalent cause of vaginal symptoms in women nationally.
3
 Data from the 
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National Health and Nutrition Survey indicate up to 1 in 3 women ages 14-49 are affected at 
any time.
3
  BV is more prevalent in African American and/or American Hispanic women than in 
Caucasians.
 1-5
 After adjusting for age, education, and poverty, BV is still three times more 
prevalent in these racial/ethnic groups than in Caucasians. 
3
 Because the social construct of 
race encompasses multiple factors including host, environment, and behavior, interpreting the 
influence of race on incidence, prevalence, and transmission of BV is complex.
11
 
While sexual transmission has been implicated in the development of recurrent BV,
19
 
the data are mixed.  Multiple epidemiologic studies show an increased risk of up to 60% for BV 
acquisition in women with multiple or new sexual partners and a protective effect from both 
incident and recurrent BV in women who report condom usage.
20
  Other data are less 
supportive of sexual transmission, such as finding BV in sexually naïve individuals.
21
  
The etiology, pathogenesis, and events that lead to the development of BV are 
incompletely understood.
19,22
 The protective effects of lactobacilli species within the vaginal 
microbial environment are well known. Several species of lactobacilli including Lactobacillus 
gasseri, L. crispatus, L. iners (a non-H2O2-producing species), and L. jensenii secrete substances 
such as lactic acid and/or hydrogen peroxide to provide bactericidal activity and an acidic pH.
23
  
Schwebke theorizes that Gardnerella vaginalis acts as a “keystone pathogen” that alters the 
vaginal microbiome causing a reduction of lactobacilli and an increase in BV-associated 
bacteria. Non-pathogenic, commensal bacteria, present in the vaginal microbiome, then aid the 
development of the well-characterized dysbiosis – a polymicrobial mix of facultative anaerobes 
that aid in the transmission and persistence of BV.
24
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Despite the prevalence of G. vaginalis in women with BV (98-100%), it is also present in 
women without BV (55%).
25
 It has been shown that genetic heterogeneity exists within 
subtypes of Gardnerella, and the species can be further classified into four clades: only clades 1 
and 3 are associated with BV.
19
 
5,10
Sequencing studies have shown that bacterial diversity 
beyond G. vaginalis subtypes is also important in the pathogenesis of BV. Women with BV have 
an average of 12.6 bacterial species while women without BV have an average of 3.3 species.
26
  
BV is also considered a biofilm infection, which consists of a complex polysaccharide matrix that 
adheres to epithelial cells in the genital tract of women. G. vaginalis is the predominant species 
while other species enhance the biofilm matrix created by G. vaginalis.
27
 
28
 The bacterial biofilm 
provides a biologic explanation for treatment resistance and recurrence, as antibiotic therapy 
alone is unable to disrupt the BV biofilm.
27
 Further studies describing the bacterial biofilm point 
to only specific strains of Gardnerella being capable of biofilm creation, potentially explaining 
why not all BV infected women will develop recurrent disease.
29
 Therefore, disruption of the 
acidic lactobacilli rich environment, proliferation, and diversification of anaerobic bacteria and 
development of an adherent polymicrobial biofilm seems to underlie the pathogenesis of BV 
and provides a biologic explanation for recurrence or persistence of infection.  
Symptoms. The typical presentation of patients with BV includes foul-smelling or fishy vaginal 
discharge.  The complaint of malodor is highly associated with BV,
3
 and may be exacerbated by 
conditions that elevate the vaginal pH such as sexual intercourse with semen deposition, or 
presence of blood.  Itching and burning are unlikely in BV but may be present when discharge 
causes secondary vulvar irritation.
30
 If vaginal or vulvar irritation is present, the clinician should 
have a strong suspicion for mixed infection with candida or other inflammatory processes.  
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Exam findings. A grey-white, thin, or watery discharge, visible in the vagina or at the vulvar 
vestibule is most commonly described by examining practitioners.  In contrast, findings of 
purulent or frothy discharge are uncommon.
1
 Since BV is not an inflammatory process, the 
presence of erythema, fissuring, or bleeding likely indicates mixed infection or alternative 
etiology. 
Diagnostic testing. Classically, at least three of the four components of Amsel’s criteria will be 
present: a thin, homogenous white discharge, an increased pH >4.5 of the vaginal fluid, release 
of an amine odor upon application of potassium hydroxide (positive whiff test), and >20% clue 
cells on saline microscopy.
32
 However, some studies have shown that two of the four Amsel 
criteria may perform just as well as three out of four
33
.  Traditional diagnostic testing with 
Amsel’s criteria and using saline microscopy allows physicians to make a more immediate 
diagnosis of BV and is relatively low cost.  The simplicity, low cost, and immediate utility of 
obtaining a vaginal pH make it a critical part of the clinical evaluation.  With saline microscopy, 
the absence of lactobacilli and/or presence of corkscrew bacilli are associated with BV.
1,8
 BV is 
not an inflammatory process and the presence of PMNs in the vaginal saline microscopy 
decreases the likelihood of BV and should raise suspicion for an alternate diagnosis or a mixed 
infection.
1,6
  
The Nugent score, which utilizes a standardized morphologic scoring system ranging 
from  0 – 10, with > 7 being diagnostic for BV of Gram-stained specimens of vaginal smears, 
remains the gold standard for BV diagnosis in the research setting but is typically not used in 
clinical settings.  Given the association of BV with other sexually transmitted infections (STIs), 
HIV and STI testing should be considered in women diagnosed with BV.
32,34
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Molecular testing can improve the accuracy of diagnosing BV and trichomoniasis and 
may be useful in cases that have not responded to therapy or when microscopy is not available 
(Table 1). 
25
   Molecular diagnostic tests include two direct DNA probe assays (Bacterial 
vaginosis/vaginitis panel and the Affirm VPIII assay) and four nucleic amplification tests (Nu 
Swab, Sure Swab, BD Max vaginal panel and the BV Panel).  These testing modalities are 
substantially more costly than saline microscopy.  The benefit of molecular technology over 
classic diagnostic methods is not yet clear when microscopy is available, and governing bodies 
such as the American College of Obstetricians and Gynecologists (ACOG) or the Infectious 
Diseases Society for Obstetrics and Gynecology (IDSOG)  have not issued official 
recommendations for their use.
25
    
Vaginal culture for bacteria is not recommended in the evaluation of BV and should be 
actively discouraged.  Cytologic testing is not reliable.  If a Pap smear mentions a shift in flora to 
predominantly coccobacilli suggesting BV, a symptomatic patient should undergo standard 
diagnostic testing and treatment as appropriate.   
Treatment. First-line therapy for acute BV is a 7-day course oral metronidazole, a 7-day course 
of intravaginal clindamycin cream or a 5-day course of intravaginal metronidazole gel (Table 
2).
32
 Clindamycin vaginal ovules have been shown to be as effective as the 7-day course of 
clindamycin.
35
 A 2009 Cochrane review showed equivalent effectiveness for oral clindamycin 
and recommended topical metronidazole and clindamycin regimens.
36
  In 2018, secnidazole 
was approved for the treatment of incident BV. Secnidazole has a much longer half-life than 
metronidazole and the single-dose regimen was found to be at least as effective as the 7-day 
oral metronidazole regimen.
37
 It should be mentioned that while single-dose secnidazole 
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performed better than placebo when fewer than three episodes of BV were reported, it was 
not better than placebo in individuals who reported four or more episodes of BV. 
22
  The U.S. 
Centers for Disease Control and Prevention (CDC) has suggested that women being treated for 
BV should refrain from sexual activity or use condoms consistently and correctly.
32
  
Greater than 50% of women will have a repeat episode of BV within 1 year of treatment 
with 7 days of metronidazole therapy.
17,18
 Recurrent BV,  defined as three or more symptomatic 
episodes within 1 year, 
31
  may be associated with multiple treatment failures over periods of 
several years or months. Failure of symptom resolution during appropriate antibiotic treatment 
should raise suspicion for mixed infection and the need for further evaluation. One of the CDC 
suggested treatment strategies for recurrent BV includes 0.75% metronidazole intravaginal gel 
daily for 10 days followed by twice-weekly intravaginal metronidazole for 4-6 months (Table 2). 
32,31b
  The CDC cautions that recurrence may be common after completion of therapy.  
With the realization that a bacterial biofilm is implicated in recurrent or persistent BV, 
disruption of the bacterial biofilm has become the target of in vitro studies.
38,39
 Boric acid 
combined with nitroimidazole therapy has been used to treat recurrent BV and has been shown 
to disrupt the biofilms of both BV and candida.
40
 A novel anti-infective, TOL-463, is a boric acid-
based vaginal gel enhanced with ethylenediaminetetraacetic acid (EDTA).   A recent phase 2 
clinical trial found that boric acid and EDTA administered as a vaginal insert showed successful 
treatment of BV (59% at test of cure).
41
 This is a similar cure rate to findings from other studies 
using imidazole therapy, and suggest a role for biofilm disruptors as novel or adjunctive 
therapies in the treatment of BV. A single pilot study that evaluated the effectiveness of the 
addition of boric acid to standard nitroimidazole suppressive therapy in cases of recurrent BV 
12 
 
 
 
showed lower rates of breakthrough infections (12% vs. 25%) while on suppression and lower 
late-recurrence rates (45% at 32 weeks vs. 66% at 28 weeks)  than in previous studies utilizing 
single-agent nitroimidazole therapy.
26
 While these results are promising, larger, prospective, 
comparative studies are recommended.   
BV is implicated in the pathogenesis of several serious disease processes such as 
preterm labor, preterm rupture of membranes, postpartum infections, persistence of HPV, 
increased HIV acquisition, pelvic inflammatory disease, and tubo-ovarian abscess formation.
12,3
 
Multiple studies have also illustrated increased acquisition of Trichomonas vaginalis, Neisseria 
gonorrhea and Chlamydia trachomatis in women with BV.
13-16
 Since BV is associated with 
adverse pregnancy outcomes, all symptomatic pregnant women should be treated for BV either 
with the oral or topical regimens of metronidazole, which have no demonstrated teratogenic or 
mutagenic effects in newborns.
32
 
Patients may ask providers about the use of probiotics for BV. Common naturopathic 
recommendations include the alteration of diet to include yogurt, using yogurt or garlic in the 
vagina or oral supplementation with probiotic species. A review and meta-analysis from 2017 
found no significant difference in the efficacy of metronidazole combined with probiotics 
compared to metronidazole alone for the treatment of BV.
42
 At this time, there is not sufficient 
evidence to support the use of probiotics for BV, and they are not recommended in the CDC 
treatment guidelines.   
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The role of male partner treatment is controversial as well designed and robust studies 
are lacking.
43
  No trials have evaluated female partner treatment. 
15 
Therefore, treatment of 
male or female partners is not currently recommended.  
Data regarding the role of circumcision in the transmission of BV is conflicting and does 
not include studies evaluating the role of circumcision and recurrent infection in female 
partners.
44
 However, it has been shown that the penile microbiome in uncircumcised males 
when compared to circumcised males, is more likely to favor BV-type microorganisms.
19,45
  
Condom use has been shown to decrease acquisition of incident BV.
46,20,19
 There is also 
suggestion that the use of condoms may reduce the incidence of recurrent BV,
46
 but it is 
difficult to draw practical conclusions from these data as a specific condom-use-strategy has 
not been studied. Therefore, specific recommendations regarding the duration of condom use 
in women affected by recurrent BV with single or multiple partners are not available.  
Inflammatory Causes  
 The most common cause of inflammatory vaginitis is trichomoniasis, diagnosed in 5-20% 
of patients reporting abnormal vaginal symptoms.
1
 Vulvovaginal candidiasis (VVC) is also a very 
common cause of inflammatory vaginitis, comprising up to 30% of diagnoses in women with 
vaginal complaints.
8
 Inflammatory cells may also be found in vaginal secretions from women 
with cervicitis or viral infections such as human papillomavirus or herpes simplex virus.  Non-
infectious forms of inflammatory vaginitis are less common but include atrophic or 
hypoestrogenic vaginitis, DIV, and mucosal erosive diseases.  
Trichomoniasis  
14 
 
 
 
Trichomonas infection affects 3.7 million persons in the United States.
32
 The prevalence 
in women 40 and over is 11% overall and is more common in women diagnosed with other STIs 
including HIV. African American women are disproportionately affected with a prevalence of 
13% compared to 1.8% of Caucasian American women.
8,32
  Trichomonas infection is associated 
with adverse health outcomes such as increased HIV transmission, preterm birth, and increased 
incidence of pelvic inflammatory disease (PID) in HIV infected women.
32
  
Symptoms. Up to 70% of women infected with trichomonas are asymptomatic.
32
 Symptoms 
reported by women with trichomonas include increased malodorous discharge that is yellow, 
green or grey in color. Itching, burning, painful urination, and vulvar irritation may also be 
reported.
47,32
  
Exam findings. Clinical descriptors of discharge include a yellow-green, frothy discharge with 
evidence of vaginal or cervical inflammation. Cervical inspection may reveal a “strawberry” or 
punctate appearance.  
Diagnostic testing. The vaginal pH in women with trichomonas infection is usually above 4.5. 
Saline microscopy will show many PMNs and motile trichomonads, which distinguishes 
trichomonal infection on microscopy from other forms of inflammatory vaginitis. Microscopy, 
however, only has a sensitivity of 51%-65%
32
 for the diagnosis of trichomoniasis.  Nucleic acid 
amplification tests (NAATs) detect 3-5 times more trichomonal infections than wet mount and 
have a sensitivity and specificity of 95%-100% with 100% concordance between urine and 
vaginal samples. Thus, NAAT testing is currently the gold standard.
32
 The CDC recommends 
retesting within 3 months for women diagnosed with a trichomonal infection, regardless of 
15 
 
 
 
partner treatment status, because of high rates of recurrence (17%).  Testing can be performed 
as soon as 28-days post-treatment.
48
  
Other testing options include a 10-minute point of care test to detect antigens via 
dipstick with a sensitivity of 82%–95% and specificity of 97%–100%.
32
 A 45-minute DNA 
hybridization probe test evaluates for T. vaginalis, G. vaginalis, and Candida albicans with a 
sensitivity of 63% and specificity of 99.9%. Neither liquid-based nor conventional pap tests are 
considered diagnostic tests for trichomonal infection as false positives and negatives have been 
reported.
32
 
Treatment. Current CDC-recommended first-line therapy is oral treatment with either 
metronidazole or tinidazole, both as a single dose (Table 3). However, a recent multi-center 
randomized control trial found the 7-day course of metronidazole to be superior to single-dose 
metronidazole for the treatment of trichomonas (11% vs 19% trichomonas positive at 4 weeks 
post-therapy). 
49
  Hence, 7 days of therapy may be indicated.  Tinidazole is slightly more 
effective than metronidazole but is considerably more expensive than generic metronidazole. 
Cure rates with standard tinidazole treatment regimens range from 92%-100% while 
metronidazole regimen cure rates range from 84%-98%.
32
 T. vaginalis has been isolated from 
multiple sources within the genital tract including the periuretheral glands, bladder, and 
Bartholin’s glands.
25
 This likely explains the increased effectiveness of tinidazole, which has a 
longer half-life and reaches higher concentrations with genital tract tissues. Metronidazole gel 
does not reach effective treatment levels within the vaginal mucosa and periurethral glands 
and is not recommended for treatment.
32
  Clinicians should advise women with trichomonal 
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infection to abstain from sex until they and their sex partners are treated. Testing for other STIs 
should be performed in persons infected with T. vaginalis.
32
 
Imidazole resistance is uncommon but emerging.
50
 Resistance to tinidazole is 
approximately 1% while metronidazole resistance is 4%-10%.
51, 50
 Most cases of recurrence are 
due to re-exposure and not a persistent infection. However, if re-exposure has been ruled out, 
treatment with either metronidazole or tinidazole may be used.  Testing for imidazole resistant 
trichomonas should be pursued with the CDC if the high dose regimen has failed after 2-3 
courses (Table 3).
52,32
  
Treatment with metronidazole for pregnant women with symptomatic trichomoniasis is 
recommended. T. vaginalis is associated with adverse outcomes such as premature rupture of 
membranes, preterm delivery, and delivery of a low birthweight infant
53
, however, no 
significant difference in perinatal morbidity after treatment has been demonstrated.  
Atrophic Vaginitis  
Hypoestrogenic vaginitis is caused by diminished serum estrogen levels that result in a 
loss of elasticity, dryness and thinning of the mucosa of the lower genital tract.
47
 Atrophic 
vaginitis is more common in postmenopausal women and symptoms such as vaginal dryness 
are reported in up to 47% of postmenopausal women. Similar symptoms are reported as 
bothersome in 3% of reproductive-age women.
54
  Causes for urogenital atrophy in 
premenopausal women include postpartum estrogen reduction, oophorectomy, premature 
ovulatory failure, anti-estrogenic medications such as tamoxifen, medroxyprogesterone 
acetate, hypothalamic amenorrhea, GnRH agonists and antagonists, and occasionally, oral 
contraceptive pills.    
17 
 
 
 
Symptoms & exam findings.  Symptoms include dyspareunia, dryness, itching, or burning.
55
 
Atrophic vaginitis may share similar findings with other forms of inflammatory vaginitis such as 
purulent discharge, vaginal erythema, and petechia.
7
 However, along with patient age or 
estrogen status, visualized atrophy on examination and evidence of parabasal cells on saline 
microscopy (Figure 2) 
47
 may help to distinguish this form of inflammatory vaginitis from the 
others. Typically, vaginal pH will be elevated above 4.5, whiff test will be negative, and 
parabasal cells may be noted, indicating a thin vaginal mucosa with fewer layers.
55 
Treatment.  The treatment of estrogen deficiency is both diagnostic and therapeutic. Topical 
estrogen should result in a relief of symptoms in women with atrophic vaginitis and can be 
continued as needed to control symptoms.
31
 Non-hormonal options include vaginal 
moisturizers and lubricants.
55
 Other FDA approved treatments for urogenital atrophy include 
systemic medications such as ospemifene
56
 and intravaginal dehydroepiandrosterone 
(Prasterone).
57
  
Desquamative Inflammatory Vaginitis  
 DIV is a chronic inflammatory process of the vagina and vestibule. It is not easily 
distinguishable from other forms of inflammatory vaginitis and is often a diagnosis of exclusion. 
It has been suggested that DIV is more common in perimenopausal and Caucasian women.
58
 
The incidence of DIV in vulvovaginal clinics has been estimated between 0.8-4.3%.
6 
However, 
knowledge of DIV as a form of vaginitis by clinicians is low and the true incidence, prevalence, 
and demographic characteristics of women with DIV are unknown.
6
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Symptoms & exam findings. The clinical features of DIV have been described as a “purulent” 
vaginitis with increased pH and inflammatory cells composed mostly of PMNs on saline 
microscopy.
7
 Diagnosis of DIV also requires an increase in parabasal epithelial cells on 
microscopy and is thus difficult to distinguish from atrophic vaginitis in postmenopausal 
women.  It is possible that there is a spectrum of DIV ranging from mild to severe in terms of 
symptoms, physical exam findings, and microscopic detail.
59
 Diagnosis of DIV requires the 
exclusion of infectious and estrogen-related causes before a diagnosis can be made, and is, 
therefore, a diagnosis of exclusion. 
Treatment. After alternative causes have been ruled out, patients with suspected DIV should 
receive a trial of intravaginal steroid or clindamycin, as described by Sobel.
60
 Clindamycin 2% 
vaginal cream every other night or 10% hydrocortisone vaginal suppository or hydrocortisone 
25 mg suppository every night for 14 days have been shown to be effective, but prolonged 
therapy of four to eight weeks is often necessary for cure.
60,7
  
Vaginal Erosive Disorders 
Patients with erosive disease may be identified via a careful physical exam. A vulvar 
biopsy may be useful, though vulvar biopsies commonly have non-specific inflammatory 
findings and can be slow to heal. Diseases that may present with vaginal erosions include 
erosive lichen planus, pemphigus vulgaris, pemphigoid, and cicatricial pemphigoid. The true 
prevalence of vaginal erosive disorders is unknown. Erosive lichen planus may be the most 
common, but there is no data available regarding the prevalence of vaginal lichen planus. The 
only available data comes from a small study of oral lichen planus which demonstrated vaginal 
19 
 
 
 
lichen planus in 51% of patients.
61
 Vulvar vestibulitis (adenitis) may also present with vaginal 
symptoms, especially in women with persistent complaints; clinicians should consider this 
entity in their differential diagnosis. 
Symptoms & Exam Findings. Erosive vaginal disease may present as shallow isolated and 
erythematous erosions of the vagina or labia minora along with purulent discharge. Non-lichen 
planus diseases may present with a combination of bullae and erosions. Mononuclear 
inflammatory cells on microscopy further suggest erosive disease.
31
 In advanced stages, vaginal 
stenosis or other architectural distortions may exist. The entire vagina may appear friable and 
serosanguinous drainage may be present.
62
  
Treatment. When an erosive disease is suspected, biopsy and histopathologic evaluation are 
warranted.
7
 Limited evidence exists regarding treatment of erosive vaginal diseases. Referral to 
clinicians experienced in managing these disorders may be the most beneficial. 
Conclusions 
The difficulty in reaching an appropriate diagnosis in women presenting with vaginal 
symptoms is due, in part, to the diverse etiologies that share common presentations and 
clinical findings. Creating proper clinical awareness and educational models is therefore 
challenging and may explain why many women are not diagnosed and treated appropriately 
after an initial evaluation. Additional epidemiologic and clinical data are needed regarding the 
less common causes of vaginitis/vaginosis and in women with recurrent vaginal symptoms.  
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Figure 1. A Diagnostic Aid for the Evaluation of Vaginal Symptoms. Reproduced and modified 
with permission from Reichman O, Sobel J. Desquamative Inflammatory Vaginitis. Best Pract Res 
Clin Obstet Gynaecol. 2014;28(7):1042-1050.  
BV - bacterial vaginosis, DIV – desquamative inflammatory vaginosis, GC – gonorrhea, NAAT – 
nucleic acid amplification test, PMN – Polymorphonuclear neutrophils, VVC – vulvovaginal 
candidiasis 
Figure 2. Parabasal cells (arrows) & PMN’s 200x magnification. With permission. Ioannis 
Mylonas, Florian Bergauer. Published 2011 in Obstetrical & Gynecologic Survey.
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Table 1. SENSITIVITY AND SPECIFICITY OF DIAGNOSTIC TESTS FOR BACTERIAL VAGINOSIS
23
 
TEST SENSITIVITY (%) SPECIFICITY (%) MANUFACTURER 
Wet mount /Amsel’s criteria 30 – 70 94 – 99  
Direct probe assays    
  BV/vaginitis panel
a, b 
  Quest Diagnostics, Secaucus, NJ 
  Affirm VPIII
b
 94 81 Becton Dickinson, Sparks, MD 
Nucleic amplification assays
 
   
  NuSwab 92 94 Laboratory Corp. of America, Burlington, NC 
  SureSwab
a 
  Quest Diagnostics, Secaucus, NJ 
  BD MAX
b
 90.5 85.5 Becton Dickinson, Sparks, MD 
  BV Panel
b 
92 95 Medical Diagnostic Labs, Hamilton TWP, NJ 
 
a 
Sensitivity and specificity not published 
b
FDA-approved 
 
Table 2. Treatment of Acute and Recurrent Bacterial Vaginosis
32
 
Acute  Recurrent
a 
Oral metronidazole 500mg daily x 7 days 
Intravaginal metronidazole daily x 10 days.  
Then, twice weekly for 4-6 months.
32a
 
Oral clindamycin 500mg twice daily x 7 days 
Oral secnidazole granules 2g single dose 
Intravaginal metronidazole 0.75% daily x 7 days  
Oral Tinidazole or metronidazole twice daily x 7 days; 
then, intravaginal boric acid 600mg daily x 21 days; 
then, intravaginal metronidazole twice weekly for 4-6 
months.
b
 
Intravaginal clindamycin 2% cream daily x 7 days 
Intravaginal clindamycin ovules daily x 3 days 
  
 
a
Recurrent bacterial vaginosis is defined as three or more episodes in 1 year.  
b
 Based on limited data. 
32b
 
 
 Table 3. Treatment of Acute and Persistent Trichomonas Vaginitis
31
 
Acute  Persistent
a 
Oral tinidazole 1000mg daily x 7 days Oral tinidazole or metronidazole 1000mg twice daily x 
7 days. Test for resistance to tinidazole and 
metronidazole after 3-4 courses. 
Oral metronidazole 500mg twice daily x 7 days 
 
a 
Re-exposure is the most common cause of recurrence. If re-exposure has been ruled out, treatment for persistent 
infection may be initiated. 
 


